Sanofi - American Depositary Shares (SNY)

Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the company’s executive vice president and head of Specialty Care. Speaking at a Morgan Stanley fireside ch

They could both outperform the market over the medium term, but one appears to have a clear edge.

The company has increased its dividend for 30 consecutive years.

Sanofi (NASDAQ:SNY) raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. The company also increased its 2030 sales ambition for Dupixent to approximately €25 billion while outlining an ongo

Add the effect of stock buybacks to the dividend, and you're looking at a total yield approaching 11%.

All three can be bought on the dip.

Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.

These stocks pay between 5.3% and 6.7% in dividends.

The stock looks cheap, but appearances can be deceiving.

Sanofi is generating some solid growth and it trades at an incredibly low valuation.

Investors can find much better opportunities.

This milestone came with an asterisk.

Recursion (RXRX) Q1 2026 Earnings Transcript

A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.

As you wait for stock prices to rebound, these three healthcare companies pay dividends with generous yields.

It will be a turbulent ride, but patient investors might come out of it much richer.